Karger Publishers, Pharmacology, 1-2(106), p. 9-19, 2020
DOI: 10.1159/000510251
Full text: Unavailable
<b><i>Background:</i></b> Extensive efforts have been made in optimizing monoclonal immunoglobulin (Ig)G antibodies for use in clinical practice. Accumulating evidence suggests that IgA or anti-FcαRI could also represent an exciting avenue toward novel therapeutic strategies. <b><i>Summary:</i></b> Here, we underline that IgA is more effective in recruiting neutrophils for tumor cell killing and is potently active against several pathogens, including rotavirus, poliovirus, influenza virus, and SARS-CoV-2. IgA could also be used to modulate excessive immune responses in inflammatory diseases. Furthermore, secretory IgA is emerging as a major regulator of gut microbiota, which impacts intestinal homeostasis and global health as well. As such, IgA could be used to promote a healthy microbiota in a therapeutic setting. <b><i>Key messages:</i></b> IgA combines multifaceted functions that can be desirable for immunotherapy.